# A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors

> **NCT07466160** · PHASE1,PHASE2 · RECRUITING · sponsor: **Mabwell (Shanghai) Bioscience Co., Ltd.** · enrollment: 280 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** 7MW3711
- **DRUG:** JS207
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT07466160
- **Lead sponsor:** Mabwell (Shanghai) Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-11
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07466160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07466160, "A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07466160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*